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Abstract
Background: Molecularly targeted drugs inhibit aberrant signaling within oncogenic pathways. Identifying the
predominant pathways at work within a tumor is a key step towards tailoring therapies to the patient. Clinical samples
pose significant challenges for proteomic profiling, an attractive approach for identifying predominant pathways. The
objective of this study was to determine if information obtained from a limited sample (i.e., a single gel replicate) can
provide insight into the predominant pathways in two well-characterized breast cancer models.
Methods: A comparative proteomic analysis of total cell lysates was obtained from two cellular models of breast
cancer, BT474 (HER2+/ER+) and SKBR3 (HER2+/ER-), using two-dimensional electrophoresis and MALDI-TOF mass
spectrometry. Protein interaction networks and canonical pathways were extracted from the Ingenuity Pathway
Knowledgebase (IPK) based on association with the observed pattern of differentially expressed proteins.
Results: Of the 304 spots that were picked, 167 protein spots were identified. A threshold of 1.5-fold was used to select
62 proteins used in the analysis. IPK analysis suggested that metabolic pathways were highly associated with protein
expression in SKBR3 cells while cell motility pathways were highly associated with BT474 cells. Inferred protein
networks were confirmed by observing an up-regulation of IGF-1R and profilin in BT474 and up-regulation of Ras and
enolase in SKBR3 using western blot.
Conclusion: When interpreted in the context of prior information, our results suggest that the overall patterns of
differential protein expression obtained from limited samples can still aid in clinical decision making by providing an
estimate of the predominant pathways that underpin cellular phenotype.
Background
Breast cancers are clinically heterogeneous [1]. Particular
molecules have been identified that are associated with
clinical prognosis. For instance, 20% to 25% of breast cancers are associated with the overexpression of HER2, and
its presence is associated with poor prognosis [2,3]. In
addition, increased ER/PR expression has been identified
in 70% of breast cancer patients. These biomarkers have
motivated a shift away from "one size fits all" approach of
treating breast cancer to developing therapies that target
specific molecules. In particular, tamoxifen, a selective
ER modulator (SERM), improves survival for patients
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with ER/PR positive tumors [4,5]. Trastuzumab, a human
monoclonal antibody was developed to bind the HER2
receptor and block its activity [6]. However, de novo or
acquired resistance to tamoxifen [7-9] and trastuzumab
[10] has been an emerging problem.
Molecularly targeted drugs, like trastuzumab and
tamoxifen, are designed to block aberrant signaling
within oncogenic pathways. Cell signaling pathways
direct the flow of information (i.e. flux) from an extracellular stimulus to the corresponding cellular response
(e.g., cellular proliferation, contact inhibition, or cellular
death). By analogy with metabolic control analysis, control of flow of information is distributed among all the
steps in a network [11-13]. This implies that an increase
in one protein does not necessarily correspond to an
increased pathway flux. Conversely, the decrease in
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expression of one protein via therapeutic modification
does not necessarily lead to a decrease in pathway flux.
Conceptually, this leads to the hypothesis that combining
gene expression measurements over group of genes that
fall within common pathways will be more effective
means of marker identification. In fact, recently it was
shown that breast cancer genes that do not exhibit a
change in their expression profile still play a central role
interconnecting deregulated genes in a protein network
[14]. The observation that onset and progression of many
diseases arises from the interactions of a number of interconnected genes has shifted the drug discovery perspective from a molecule-centric to a network/pathwaycentric approach [15]. Proteomics provides an attractive
platform for interrogating pathway flux as measuring
actual protein levels instead of measuring proxy mRNA
levels maybe more informative in spite of added experimental complexity [16].
One of the most commonly used techniques for proteomic profiling is 2DE based protein separation in combination with mass spectrometry based identification.
Using this approach, in addition to analyzing proteins in
the blood, tumor tissues are being examined to yield
insights about molecular pathways that are altered in cancer progression. While 2-DE based high-throughput proteomic data reveal proteins that are differentially
regulated, different sources of biological and analytical
variations affect the statistical importance of these results
[17]. These can be addressed using an experimental
design that incorporates several technical and biological
replicates to account for variations at two levels, within
gels and within samples, respectively [18-20]. This puts a
demand on the sample amount and composition as proteomic analysis of breast cancer biopsies is complicated
due to heterogeneity of cellular phenotypes contained in
the sample [21]. While laser capture microdissection
(LCM) can provide a relatively homogeneous sample by
concentrating on the cell type of interest, generating
enough sample for a conventional proteomic study is
laborious with a minimum of 100,000 cells and a dissection time in tens of hours required for one 2D-PAGE [22].
Given the desire to aid in clinical decision-making, the
ability to obtain sufficient clinical sample presents a significant challenge. In the case of sample that is insufficient to carry out a proteomic study with multiple
replicates, like in the case of an early stage breast tumor,
does the information obtained from a single gel replicate
still provide insight into the predominant cell signaling
pathway at work in a cell?
Thus the objective of this study was to identify predominant pathways and protein interaction networks in two
breast cancer phenotypes using prior information. Given
the conservation of genetic information and marker
expression between tumors and their corresponding cell
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lines [23-25], we have used well characterized model systems in our study. The central hubs of protein interaction
networks obtained using prior information were validated to establish confidence in the protein expression
patterns.

Methods
Cell culture and reagents

The human breast cancer cell lines (BT-474 and SK-BR-3)
were kindly provided by Dr. Jia Luo (Health Sciences
Center; West Virginia University, WV). Cells were grown
in 75-cm2 plastic tissue culture flasks (Costar Corning;
Corning, NY) in a humidified incubator at 37°C and 5%
(v/v) CO2. The BT-474 cells were routinely maintained in
Rosewell Park Memorial Institute (RPMI) 1640 medium
(Mediatech, Inc., Herndon, VA) supplemented with 10%
(v/v) heat inactivated fetal bovine serum (FBS) (Hyclone,
Inc., Logan, UT), 0.3% (w/v) L-glutamine, 1% (v/v) penicillin/streptomycin (BioWhittaker, Walkersville, MD) and
10 ng/mL insulin (Sigma, St Louis, MO). SK-BR-3 cells
were maintained in Improved Modified Eagle Medium
(IMEM) Zn2+ option (Invitrogen) containing 4 mM Lglutamine, 2 ml/L L-proline, 50 μg/mL gentamicin sulfate
supplemented with 10% FBS (Hyclone) and 1% penicillin/
streptomycin (BioWhittaker). Cells were passaged at 1:5
dilution with fresh medium every 5 days.
Preparation of cell lines for 2-DE

Cells were grown to approximately 80% confluence.
Growth medium was removed from dishes and cells were
washed twice with 10 mL Phosphate Buffered Saline
(PBS) to remove dead cells as many extracellular proteins
as possible. Cells were made non-adherent by incubating
the flasks at 37°C for 10 min in the presence of trypsin
(BioWhittaker). Trypsin was neutralized by the addition
of FBS. Cells were then washed twice with PBS and harvested at 1,200 rpm at 4°C for 10 min. Sufficient precaution was taken to get rid of PBS to eliminate salts that
could possibly interfere with the 2DE. Cells were incubated in lysis buffer (7M Urea, 2M thiourea, 2% (w/v)
CHAPS) for 30 min on ice and sonicated five times in an
ultrasonic water bath, where each sonication was performed for 10 s followed by 10 s cooling interval on ice.
Cell debris were pelleted by centrifugation at 14,000 rpm
for 40 min at 4°C. The supernatant was aliquoted in fresh
tubes and stored at -80°C. The protein concentration was
determined using BCA protein assay kit (Pierce).
2-D Electrophoresis

For each cell line, 500 μg of cell lysate was mixed with
rehydration buffer (7M urea, 2M thiourea, 2% CHAPS,
1% DTT, 2% IPG buffer, 0.002% bromophenol blue) and
incubated for 1 h at room temperature prior to rehydration on Immobilized pH Gradient (IPG) strips pH 3-10
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NL, 24 cm, (GE Healthcare, Uppsala, Sweden) for 12 h at
25°C. Isoelectric focusing was done using Ettan IPGphor
apparatus (Amersham Biosciences) for a total of 90 kVh
at 50 μA per strip at 20°C. Thereafter, IPG strips were
equilibrated in 75 mM Tris-HCl pH 8.8, 6M urea, 30% (v/
v) glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol
blue and 1% (w/v) DTT for 30 min. A second equilibration step was done for another 30 min by replacing the
DTT with 2.5% iodoacetamide. Equilibrated strips were
transferred onto 24 cm 12% uniform precast SDS-polyacrylamide gels (Jule, Inc., Milford, CT) poured between
non-fluorescent glass plates. IPG strips were sealed with
0.5% (w/v) low melting point agarose in SDS running buffer containing bromophenol blue. Gels were run in Ettan
DALTsix Larger Vertical System (Amersham Biosciences)
at 30mA per gel at room temperature, until the dye front
had run off the bottom of the gels.
Gels were fixed in 10% (v/v) methanol, 7% (v/v) acetic
acid overnight, washed in 18 MΩ water, and stained overnight with SYPRORuby dye (Bio-Rad). Excess dye was
removed by washing twice with 18 MΩ water in a dark
room. Gels were imaged using the Typhoon 9400 scanner
(Amersham Biosciences) at 200 μm resolution with a
488nm laser with 610nm band pass filter at normal sensitivity under fluorescence acquisition mode. Data were
saved in .gel format using ImageQuant software (Amersham Biosciences). The 2-DE results are representative of
three biological replicates.
Image analysis

The images were analyzed using SameSpots software
from Nonlinear Dynamics. Saturated and damaged areas
of the gels were ignored in the analysis by selecting a
region of interest (ROI). The images were warped using
automatic and manual vectors to a reference image that
was automatically selected based on the gel containing
the most spots. Normalized spot volumes were generated
from the optical densities for each individual spot to the
ratio of the total spot volume in each gel. 304 differentially expressed protein spots were chosen for further
analysis.
In-gel digestion

The gel spots of interest were excised using an Ettan Spot
Picker (Amersham Biosciences) fitted with a 1.5-mm spot
picker head. Briefly, specified excised spots were reduced
in DTT (10 mM, 60°C, 10 min) and alkylated with iodoacetamide (100 mM, room temperature, 45 min) in a dark
room. The gel pieces were dehydrated in acetonitrile for
10 min. Then the gel pieces were vacuum dried and rehydrated with 10 μL of digestion buffer (10 ng/μL of trypsin
(Promega; Madison, WI) in 25 mM NH4HCO3) and covered with 10 μL of NH4HCO3. The samples were incubated for 16 h at 37°C to allow for complete digestion.

Page 3 of 12

Peptides were extracted from gel plugs by sonication in
2.5 μL 5% formic acid.
MALDI-TOF MS analysis

MALDI-TOF-MS system model Micromass MALDI-R
(Waters®) was used to obtain the peptide mass fragment
spectra as recommended by the manufacturer. Protein
digest solutions were mixed at a 1:1 ratio with the
MALDI matrix α-cyano-4-hydroxycinnamic acid
(CHCA) (Sigma-Aldrich Fluka; St. Louis, MO). 1 μL of
tryptic peptide sample was applied to the MALDI plate
and allowed to dry. The MALDI-TOF MS was operated
in the positive ion delayed extraction reflector mode for
highest resolution and mass accuracy. Peptides were ionized/desorbed with a 337-nm laser and spectra were
acquired at 15 kV accelerating potential with optimized
parameters. The close external calibration method
employing a mixture of standard peptides (Applied Biosystems) provided mass accuracy of 25-50 ppm. Internal
calibration was performed with the monoisotopic peak of
adrenocorticotropic hormone (ACTH) (18-39) peptide
(m/z: 2465.1989). Mass spectral analysis for each sample
was based on the average of 300 laser shots. Peptide
masses were measured from m/z: 800 to 3,000. The peak
lists containing the m/z ratio and corresponding intensity
values were exported to Microsoft Excel for further processing.
Protein identification using peptide mass fingerprinting
(PMF)

Peptide mass fingerprints for each of the 304 proteins
were entered in an Excel spreadsheet along side each
other. To optimize the database searching, the list of peptide mass peaks from the spectrum of each sample was
processed and background peaks that were observed in
greater than 10% of the PMF's were eliminated to
improve the efficiency of database searching [26]. MASCOT http://www.matrixscience.com, Aldente (ExPASy)
and MS-Fit (Protein Prospector; University of California,
San Francisco) were each used to query the UniProtKB/
Swiss-Prot human database with the corresponding
monoisotopic peptide mass fingerprints with the following settings: peptide mass tolerance of 50 ppm, one
missed cleavage site, one fixed modification of carboxymethyl cysteine, one variable modification of methionine
oxidation, and no restrictions on protein molecular mass
or isoelectric point. The protein identities reported were
ranked high in at least two of the three algorithms used.
Ingenuity pathway Analysis

Differentially regulated proteins identified by 2DE and
PMF were further analyzed using Ingenuity Pathway
Analysis (IPA; Ingenuity Systems, Mountain View, CA;
http://www.ingenuity.com). IPA was used to interpret the
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differentially expressed proteins in terms of an interaction network and predominant canonical pathways. The
Ingenuity Pathways Knowledge Base (IKB) is a regularly
updated curated database that consists of interactions
between different proteins culled from scientific literature. IPA uses this database to construct protein interaction clusters that involve direct and indirect interactions,
physical binding interactions, enzyme-substrate relationships, and cis-trans relationships in transcriptional control. The networks are displayed graphically as nodes
(proteins) and edges (the biological relationship between
the proteins).
A protein interaction network was generated as follows.
A dataset containing the upregulated proteins, called the
focus proteins, for a particular cell line was uploaded into
the IPA. These focus proteins were overlaid onto a global
molecular network developed from the information in
the IKB. Networks of these focus proteins were then algorithmically generated by including as many focus proteins
as possible and other non-focus proteins from the IKB
that are needed to generate the network based on connectivity.
Canonical pathways are identified from the IPA library
based on their significance to the dataset. The significance of the association between the dataset and the
canonical pathway is measured in two ways: a) a ratio of
the number of proteins in the dataset that map to the
pathway divided by the total number of proteins that exist
in the canonical pathway and b) a p-value that is obtained
by comparing the number of genes/proteins of interest
relative (i.e., focus genes) to the total number of genes/
proteins in all functional/pathway annotations stored in
the Ingenuity Pathways knowledge base (i.e. a right-tailed
Fisher's exact test of a 2 × 2 contingency table with the
Benjamini-Hochberg correction for multiple hypothesis
testing). The 2 × 2 contingency table is shown in Table 1,
where K is the number of genes/proteins of interest (i.e.,
focus genes) and N is the total number of genes/proteins
in all pathway annotations. This test is a standardized
choice in the IPA estimate of statistically significant findings. The null hypothesis tested was that the pathways
associated with the upregulated proteins were likely to be
observed by random chance alone. A low p-value sug-

gests that the pathways associated with the upregulated
proteins were not observed by random chance alone.
Western blotting

For western blot analysis, 10-30 μg of total cell lysate was
separated by SDS-PAGE using a 12% Tris polyacrylamide
gel with a 4% stacking gel at 75 V for 4 h. Proteins were
transferred onto Bio Trace PVDF membrane (PALL Life
Sciences; Pensacola, FL) at 42 V for 1.5 h. Blots were
washed in Tris Buffered Saline (TBS) for 5 min at room
temperature, blocked for 1 h in TBS + 0.1% Tween 20
(TBS/T) plus 5% dry milk at room temperature and then
washed three times in TBS/T. Blots were incubated overnight at 4°C with primary antibodies specific for IGF-1R
(sc-9038), α-Enolase (sc-100812), GAPDH (sc-25778) (all
from Santa Cruz Santa Cruz, CA), Ras (BD Biosciences,
610001) and Profilin (Millipore, AB3891) in TBS/T plus
5% dry milk. The next day, blots were washed three times
in TBS/T, incubated for 1 h at room temperature with
anti-biotin (Cell Signaling Technology, Inc., Danvers,
MA, 7727) and either a goat anti-mouse IgG-horseradish
peroxidase (HRP) (BD BioSciences, 554002) or a goat
anti-rabbit IgG-HRP (Sigma-Aldrich, A0545). Finally, the
blots were washed three times in TBS/T, developed using
LumiGLO reagent (Cell Signaling Technology, Inc., Danvers, MA, 7003) and bands were visualized on KODAK
Biomax light film (Fisher Scientific). Densitometric analysis was performed using ImageJ software (National
Institute of Health) and protein levels were normalized to
GAPDH protein levels for each sample. Given the uncertainty in estimating the level of expression in both cell
lines, an empirical Bayesian approach was used to establish the level of confidence associated with differential
expression between BT474 and SKBR-3 given the available data [27]. Levels of expression were log-transformed
to minimize potential bias in estimating the expression
ratio, R, as follows: log10 (XBT474) = R + log10 (XSKBR3). A
Markov chain Monte Carlo algorithm was used to estimate the posterior distribution in the differential expression coefficient. An initial unbiased gaussian prior
distribution was used to propose new steps in the Markov
chain. The prior distribution was scaled to achieve an
acceptance fraction of 0.4. The Gelman-Rubin potential
scale reduction factor was used to estimate convergence

Table 1: 2 × 2 contingency table used for testing the significance of gene/protein enrichment in all IKB pathway
annotations.
Focus Genes
Genes associated with pathway
Genes not associated with pathway
Column Total

Non-focus Genes

Row Total

k

n-k

n

K-k

(N - n) - (K - k)

N-n

K

N-K

N
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of three independent Markov chains to the posterior distribution [28]. Posterior estimates of the expression ratio
were obtained from the tails of the three independent
chains following convergence.

Results
Identification of differentially expressed proteins
2DE and Image Analysis

Three biological replicates for each cell line were
obtained to ensure that the 2DE protocol provided consistent results. Qualitative criteria were used to determine the consistency among the three biological
replicates (i.e., the images obtained from all three replicate were visually similar). A single replicate from each
cell line was selected for further analysis. Figure 1 depicts
a representative pattern of cellular proteome obtained
after 2DE of total cellular extracts from BT474 (Figure
1A) and SKBR3 (Figure 1B) cell lines. Quantitative analysis was restricted to a region of interest that spanned an
isoelectric focusing range of 4-9 and an approximate
molecular weight range of 15 - 70 kDa. A total of 866
spots were identified in common between the gel images
from each cell lines within this region of interest.
Peptide mass fingerprinting

Of the 866 spots identified to be common between both
the gels using Progenesis SameSpots, spots that were not
differentially expressed or detected in streaks were
excluded from further analysis. 304 well resolved protein
spots that were differentially expressed by at least 1.1-fold
were excised from the gel, subjected to trypsin digestion
and MALDI-TOF analysis. Using the resulting peptide
mass fingerprints, 167 proteins were identified using
Mascot as a primary database search algorithm, out of
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Figure 1 Two-dimensional proteomic profile of breast cancer cell
line A) BT474, B) SKBR3. The first dimension represents a section of
the gel spanning pH 4-9. The second dimension is a 12% PAGE spanning molecular weights 10-70 kDa. Gels were stained with SYPRO Ruby
and imaged on a Typhoon 9400 scanner. The circles and squares in
panel A and B, respectively, identify picked spots. Identified proteins
are labeled with ID numbers, shown in Additional File 2, Table S1.

which 135 were unique. A subset of 62 identified proteins
that were differentially regulated by at least 1.5-fold is
shown in Additional file 1, Table II. More than 95% of the
spots had sequence coverage exceeding 25%. In a majority of the cases, the identified proteins were the only candidate with significant score leading to their
unambiguous identification. However, in some cases two
different algorithms, MS-Fit and Aldente, were used to
provide support for the protein identity from the PMF in
order to minimize false positive identifications. Agreement between the apparent Mr and pI observed from 2DE gels and the theoretical values of the identified proteins provided additional support for positive identification. A small subset of the identified proteins exists in
multiple forms, as they were associated with multiple
protein spots. This may be due to either protein degradation by proteases and formation of protein fragments or
post-translational modifications [29] such as phosphorylation and carbamylation which is common with proteins
in urea buffer and/or different isotypes. A list of all the
identified proteins with their molecular weight, isoelectric point, rank, score and sequence coverage using the
three algorithms is provided (Additional file 2, Table S1).
Protein distribution according to function, subcellular
localization and fold-change

Combining proteomics techniques with MALDI-TOF
MS analysis enabled positive identification of 167 proteins, representing a broad range of functional and compartmental classes. The proteins were assigned a
biological process and subcellular localization according
to Gene Ontology (GO). Figure 2 displays the distribution
of proteins across various biological processes (Figure
2A), subcellular compartments (Figure 2B) and foldchange in expression (Figure 2C) across the two cell lines.
The largest fraction of identified proteins was enzymes
that belonged to the metabolism group, necessary for the
cell's ATP turnover. Other major groups of proteins
involved initiation and elongation factors involved in protein synthesis, structural proteins like profilin and cofilin
involved in the assembly and rearrangement of the
cytoskeleton, and protection proteins that are involved in
protecting the cell from oxidative stress (heat shock protein beta-1) and by degradation of misfolded proteins
(UV excision repair protein RAD23 homolog B). Many
proteins are multifunctional and shuttle between different cellular compartments in different cellular contexts.
For example, Cofilin-1 is present in cytoplasm as well as
nucleus and alpha-enolase is present in cytoplasm and
cell membrane. Protein DJ-1 plays a role in transcription,
acts as a chaperone and protects neurons against oxidative stress. Similarly, alpha-enolase is a multifunctional
enzyme that plays a key role in glycolysis and in various
processes such as growth control and hypoxia tolerance.
The differentially expressed proteins represent a diverse
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C

Figure 2 Percent distribution of 135 uniquely identified proteins according to A) Biological process, B) Subcellular location, C) Fold-change
according to GO annotation terms.

sampling cross-section of different biological processes
and subcellular compartments. Proteins deregulated by
1.5-fold shown in Additional file 1, Table II formed the
dataset for pathway analysis and network generation.
Pathway analysis and network generation using IPA

Pathway analysis was performed to relate the differentially expressed proteins to canonical biological pathways.
Canonical pathway analysis identified the pathways from
the IPA library of canonical pathways that were most significant to the proteins expressed differentially. The prior
information used in this analysis contains list of canonical
pathways and associated proteins. A Benjamini-Hochberg corrected Fischer's exact test was used to calculate
the p-values associated with a canonical pathway [30].
Additionally, a ratio determining the number of focus
molecules to overall molecules in each pathway was also
used to associate canonical pathways to the dataset. The
results from this pathway analysis are summarized in Figure 3A. The most significant canonical pathway in BT474
cell line was Regulation of Actin-based Motility by Rho
when ranked by significance (p-value < 3.7 × 10-5) as well
as by ratio (4.35E-02). The most significant canonical
pathway in SKBR3 cell line when ranked by significance
(p-value < 9.1 × 10-5) was Glycolysis/Gluconeogenesis
and when ranked by ratio (4.00E-02) was Inositol metabolism (p-value < 3.5 × 10-2). In general, deregulated proteins in BT474 and SKBR3 were found to be
predominantly associated with cell motility pathways and
metabolic pathways, respectively.
These proteins were uploaded and mapped to corresponding "gene objects" in the Ingenuity Pathways
Knowledge Base (IPKB). The prior information used in
this analysis is a master gene interaction network curated
from scientific literature. IPA then generates biological
interaction networks between mapped focus genes (data
set) and all other gene objects stored in the knowledge
base. The IPA networks are reported in the form of a

graph. The nodes of the graphs are associated with a particular gene while the edges refer to relationships identified from the literature in the IPKB. Ingenuity Pathway
Analysis computes a score derived from a p-value,
adjusted for multiple hypothesis testing, that indicates
the likelihood of the focus genes in a network being
observed together due to random chance. A score of 6 or
greater (i.e., p-value < 10-6) indicates that there is a one in
million chance of the observed subset of focus genes
being observed together in a network due to random
chance alone. Four networks were generated for BT474
using our data of which the top two networks shown in
Figure 4 had functions associated with cancer (Figure 4A)
and cell morphology (Figure 4B). Similarly, five networks
were generated for SKBR3 of which the top two networks
shown in Figure 5 had functions associated with cellular
development (Figure 5A) and cell cycle (Figure 5B). Additional file 3, Table III shows the networks associated with
BT474 and SKBR3 cell lines with the list of all proteins
associated with focus genes of a network. Proteins contained within our data are highlighted in bold. The top
two networks generated for BT474 exhibited a score of 37
containing 15 focus genes and a score of 22 containing 10
focus genes, respectively. Similarly, the top two networks
generated for SKBR3 exhibited a score of 42 containing
17 focus genes and a score of 27 containing 12 focus
genes, respectively. At the core of the network, lie one or
more major hubs where multiple connections from other
nodes in the network converge on or diverge into. For
example, in the BT474 network there is a direct interaction between IGF-1R and PI3KR1. The hub node in
SKBR3 is the HRas which has direct interactions with
insulin receptor and guanine nucleotide binding protein.
On the other hand, some nodes in the network figures are
"hanging" (e.g. TMEM126B, LCMT2, IER5, etc. in Figure
5A) and do not form a network loop by connecting to no
more than one node. Due to their association with one of
the central nodes in the network (e.g. HNF4A in Figure
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A

B

Figure 3 Significant canonical pathways (p-value < 0.05) for BT474 (blue) and SKBR3 (red) cell lines using 1.5-fold A) deregulated proteins
and B) deregulated genes. The negative of the log10(p-value) and ratio are plotted on the primary and secondary Y-axis respectively.

5A) they get "swept" up in network analysis. In Figures 4
and 5, the locations of the nodes within the IPKB generated networks are highlighted in different colors that represent how the protein was identified and confirmed.

Validation of results by Western Blotting Analysis

Immunoblotting was used to validate the proteomic profiling and IPA network analysis as shown in Figure 6. Two
differentially expressed proteins identified by 2-DE (Pro-
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B

Figure 4 Differentially expressed proteins for BT474 cell line were analyzed using a manually curated structured network tool (Ingenuity
Pathway Analysis). A) Network ID 1 (p-value < 10-37) with function associated with cancer, B) Network ID 2 (p-value < 10-22) with function associated
with cell morphology. White nodes are proteins identified by IPA, grey nodes are proteins identified by IPA and 2-DE, blue node is identified by IPA
and validated by immunoblotting, and red node is identified by IPA and 2-DE, and confirmed by immunoblotting.

filin-1 and Alpha-enolase) and two membrane proteins in
the protein network identified by IPA (IGF1R and Ras)
were selected for validation. The rationale for selection of
these proteins is as follows. Profilin-1 and alpha-enolase
were the most differentially expressed proteins according
to the proteomic data. IGF1R and Ras were selected
because these proteins are the major hubs in their respective networks and to offset the bias that proteomics has
against membrane proteins that limits their detectability.
IGF1R has been found to be both significantly overexpressed [31-33] and highly activated [34] in cancer cells
with respect to its status in normal breast tissue. Similarly, Ras is abnormally activated in breast tumors overexpressing Her2 [35]. Moreover, IGF1R and Ras are integral
membrane proteins that are typically difficult to isolate
and observe using 2DE [36] and occupied central positions in the protein interaction network. GAPDH was
used to normalize the relative expression levels of the
proteins. Western blotting analysis confirmed the general
trend of expression was similar to 2-DE. Profilin-1 was
up-regulated 15-fold in BT474 in cell culture as revealed
by 2-DE and image analysis and up-regulated 1.4-fold (p <
0.01) as revealed by densitometric analysis of the western

blots. Alpha-enolase was up-regulated 5-fold in SKBR3 in
cell culture while maximum expectation value obtained
from densitometric analysis of the western blot results
suggests a 1.3-fold increase (p < 0.03). The western blot
analysis suggests that Ras was overexpressed about 1.26fold in SKBR3 (p < 0.03) and IGF1R was up-regulated
1.07-fold in BT474 (p < 0.001).
Findings from the western blot were in accordance with
the results from proteomic analysis. IGF1R and profilin
were up-regulated in BT474 and Ras and alpha-enolase
were up-regulated in SKBR3. The change in density-fold
from 2DE to western blots can be attributed to the semiquantitative nature of immunoblotting as well as the differences in the dynamic ranges of photographic quantification of chemiluminiscent and fluorescent methods of
detection for immunoblotting and 2-DE respectively.

Discussion and Conclusion
It is the specific biological question that shapes the design
of experiments [20]. For example, a common approach is
to detect changes in expression in each spot, considered
individually, that is consistently above a threshold determined by the system's experimental noise. Implicitly this
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Figure 5 Differentially expressed proteins for SKBR3 cell line were analyzed using a manually curated structured network tool (Ingenuity
Pathway Analysis). A) Network ID 1 (p-value < 10-42) with function associated with cellular development, B) Network ID 2 (p-value < 10-27) with function associated with cell cycle. White nodes are proteins identified by IPA, grey nodes are proteins identified by IPA and 2-DE, blue node is identified
by IPA and validated by immunoblotting, and red node is identified by IPA and 2-DE, and confirmed by immunoblotting.

work reflected a desire to strike an optimal balance
between the amount of data required and the ability to
infer, with predictive potential, differentially activated
pathways in two cancer models. Duncan and Hunsucker
have used an engineering term - fitness-for-purpose - to
characterize experimental design in proteomics where
different constraints; such as limits on biological samples,
effective use of resources, and how the information will
be used; shape the experimental design [37]. To strike a
meaningful balance between these constraints, we
hypothesized that a single gel replicate was sufficient to
infer, with predictive potential, cell signaling pathways
and protein networks that are differentially regulated
between two breast cancer models. We demonstrated the
predictive potential by validating the inferred differentially regulated cell signaling pathways using previously
reported gene expression data [38] and by validating the
inferred protein networks by western blot. Using previously reported gene expression data, we have attempted
to minimize potential bias in our results introduced by
our protocols (i.e., subtle differences in tissue culture or
proteomics workflow). In cases where there is less prior
information, such as a proteomic analysis of primary tis-

sue, independent analysis of other gel replicates could
help establish the confidence in the inferred differentially
regulated cell signaling pathways. Weitzel et al. [39]
recently described such an approach, where they used an
additional gel replicate to confirm the upregulated pathways.
The cellular origins and predominant signaling pathways within these two cell lines are quite different. BT474
is derived from a solid invasive ductal carcinoma in the
breast [40] while the SKBR3 cell line is derived from pleural effusion adenocarcinoma [41]. The aggressiveness of
these cell lines are different as BT474 is ER+/PR+ with a
high in vitro invasion capability whereas SKBR3 is ER-/
PR- with a low in vitro invasion capability. The aggressiveness of BT474 is supported by finding that the regulation of actin based motility by Rho and actin cytoskeleton
signaling pathways were enhanced. In contrast, metabolic
pathways like amino acid biosynthesis and glycolysis/gluconeogenesis were more pronounced in SKBR3 cell line.
To compare our results against gene expression data for
the BT474 and SKBR3 cell lines, we used the mRNA
expression data from the study of a collection of breast
cancer cell lines. The gene expression data was reported
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Figure 6 Validating the BT-474 and SKBR-3 protein interaction
networks. A) Representative western blots for IG1R, alpha-enolase,
profilin and Ras with GAPDH as loading control. B) Bayesian-MCMC estimate for the significance of differential expression within the two cell
lines.

as a matrix of probe sets by cell lines in which value is the
calculated log abundance of each probe set gene for each
cell line. Gene expression values were centered by subtracting the mean value of each probe set across the cell
line from each measured value. To calculate the fold-difference between the two cell lines, these log abundance
gene expression values were subtracted from each other.
All the up-regulated genes for BT474 (8663 genes) and
SKBR3 (8237 genes) were uploaded into the IPA. As
shown in Additional File 4, Table S2, the top 5 associated
network functions for BT474 had an identical significance score of 27 and were as diverse as cancer, skeletal
disorder and dermatological diseases. Similar analysis for
SKBR3 gene expression showed the top 5 functions had
an identical significance score of 25 and were as varied as
embryonic development, hematological system development, and lipid metabolism. The canonical pathway analysis applied to all of the differentially expressed genes
revealed that none of the canonical pathways for either
cell lines were significant (Additional file 5, Figure S1).
This is because the multiple-testing criteria raise the
threshold for significance such that none of the embed-

ded gene expression patterns within the dataset provide a
sufficiently strong signal to surpass this increased threshold. The threshold for gene expression data was increased
by setting the cut-off value to be the same as protein
expression data which was 1.5-fold. The resulting analysis
for BT474 dataset which consisted of 506 genes showed 4
out of top 5 associated network functions to be related to
cancer with scores better than 13 as shown in Additional
File 6, Table S3. The most significant pathway for this
analysis was IGF-1 signaling pathway with p-value < 1.2 ×
10-4 (Figure 3B). For 304 genes which were up-regulated
by a factor of 1.5-fold in SKBR3, 4 out of 5 associated network functions were related to cell death and cancer and
had scores better than 11. The most significant pathway
was urea cycle and metabolism of amino groups with a pvalue < 6.45 × 10-4 (Figure 3B).
The group of pathways in SKBR3 cell line associated
with our protein expression data was in agreement with
the group of pathways associated with gene expression
data. In BT474 cell line, though the top pathways for protein expression data were associated with cell motility
and the pathway for gene expression data was associated
with IGF-1 signaling, they are both associated with proliferation [42] and resistance to apoptosis [43,44] in a
broader sense. The number of focus molecules for the
protein datasets involved in the top two networks for
BT474 and SKBR3 were 25 and 29 which was 89.2% and
85.2% respectively of the total dataset; similar number for
the gene datasets were 8.3% and 10.8% for BT474 and
SKBR3 respectively, suggests that proteomics provides
greater information per observation relative to gene
expression.
In summary, experimental designs that consider each
protein individually place a high burden on clinical samples. In cases where a sample is limited, a single replicate
is unable to establish whether a single protein can be used
as a biomarker. Our results do suggest that in a non-ideal
case scenario, the overall pattern of differential protein
expression can still be used, in conjunction with prior
information, to infer pathways that underpin differences
in cell phenotype. This information may prove helpful in
tailoring therapies to the patient.

Additional material
Additional file 1 Table II (Microsoft Powerpoint): Proteins deregulated 1.5-fold or more in both the cell lines.
Additional file 2 Table S1 (Microsoft Excel): List of identified proteins
labeled in Figure 1.
Additional file 3 Table III (Microsoft Powerpoint): Top network associated functions generated using proteins deregulated 1.5-fold or
more.
Additional file 4 Table S2 (Microsoft Powerpoint): Top network associated functions generated using all up-regulated genes.
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Additional file 5 Figure S1 (Microsoft Powerpoint): Top 11 identified
canonical pathways for BT474 (blue) and SKBR3 (red) cell lines using
all deregulated genes. The negative of the log10(p-value) and ratio are
plotted on the primary and secondary Y-axis respectively.
Additional file 6 Table S3 (Microsoft Powerpoint): Top network associated functions generated using 1.5-fold up-regulated genes.
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